Availability of anticancer biosimilars in 40 countries

Hui Yao Huang; Da Wei Wu; Fei Ma; Zhi Lei Liu; Ju Fang Shi; Xia Chen; Shu Hang Wang; Hong Fang; Ying Bai; Yue Yu; Yuan Fang; Chao Sun; Qi Fan; Ying Wu; Rui Hua Fan; Cai Yun Zhou; Bao Xia He; Min Dai; Ning Li; Bing He Xu; Yan Sun; Jie He

doi:10.1016/S1470-2045(19)30860-5

Availability of anticancer biosimilars in 40 countries

Hui Yao Huang, Da Wei Wu, Fei Ma, Zhi Lei Liu, Ju Fang Shi, Xia Chen, Shu Hang Wang, Hong Fang, Ying Bai, Yue Yu, Yuan Fang, Chao Sun, Qi Fan, Ying Wu, Rui Hua Fan, Cai Yun Zhou, Bao Xia He, Min Dai, Ning Li, Bing He XuYan Sun, Jie He

Accounting, School Of

Research output: Contribution to journal › Comment/debate

8 Scopus citations

Original language	English
Pages (from-to)	197-201
Number of pages	5
Journal	The Lancet Oncology
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/S1470-2045(19)30860-5
State	Published - Feb 2020

Access to Document

10.1016/S1470-2045(19)30860-5

Cite this

Huang, Hui Yao ; Wu, Da Wei ; Ma, Fei ; Liu, Zhi Lei ; Shi, Ju Fang ; Chen, Xia ; Wang, Shu Hang ; Fang, Hong ; Bai, Ying ; Yu, Yue ; Fang, Yuan ; Sun, Chao ; Fan, Qi ; Wu, Ying ; Fan, Rui Hua ; Zhou, Cai Yun ; He, Bao Xia ; Dai, Min ; Li, Ning ; Xu, Bing He ; Sun, Yan ; He, Jie. / Availability of anticancer biosimilars in 40 countries. In: The Lancet Oncology. 2020 ; Vol. 21, No. 2. pp. 197-201.

@article{775e96d198e94764a5c3010d489e924c,

title = "Availability of anticancer biosimilars in 40 countries",

author = "Huang, {Hui Yao} and Wu, {Da Wei} and Fei Ma and Liu, {Zhi Lei} and Shi, {Ju Fang} and Xia Chen and Wang, {Shu Hang} and Hong Fang and Ying Bai and Yue Yu and Yuan Fang and Chao Sun and Qi Fan and Ying Wu and Fan, {Rui Hua} and Zhou, {Cai Yun} and He, {Bao Xia} and Min Dai and Ning Li and Xu, {Bing He} and Yan Sun and Jie He",

year = "2020",

month = feb,

doi = "10.1016/S1470-2045(19)30860-5",

language = "English",

volume = "21",

pages = "197--201",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "2",

}

Availability of anticancer biosimilars in 40 countries. / Huang, Hui Yao; Wu, Da Wei; Ma, Fei; Liu, Zhi Lei; Shi, Ju Fang; Chen, Xia; Wang, Shu Hang; Fang, Hong; Bai, Ying; Yu, Yue; Fang, Yuan; Sun, Chao; Fan, Qi; Wu, Ying; Fan, Rui Hua; Zhou, Cai Yun; He, Bao Xia; Dai, Min; Li, Ning; Xu, Bing He; Sun, Yan; He, Jie.

In: The Lancet Oncology, Vol. 21, No. 2, 02.2020, p. 197-201.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Availability of anticancer biosimilars in 40 countries

AU - Huang, Hui Yao

AU - Wu, Da Wei

AU - Ma, Fei

AU - Liu, Zhi Lei

AU - Shi, Ju Fang

AU - Chen, Xia

AU - Wang, Shu Hang

AU - Fang, Hong

AU - Bai, Ying

AU - Yu, Yue

AU - Fang, Yuan

AU - Sun, Chao

AU - Fan, Qi

AU - Wu, Ying

AU - Fan, Rui Hua

AU - Zhou, Cai Yun

AU - He, Bao Xia

AU - Dai, Min

AU - Li, Ning

AU - Xu, Bing He

AU - Sun, Yan

AU - He, Jie

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85078412663&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30860-5

DO - 10.1016/S1470-2045(19)30860-5

M3 - Comment/debate

C2 - 32007192

AN - SCOPUS:85078412663

VL - 21

SP - 197

EP - 201

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 2

ER -

Availability of anticancer biosimilars in 40 countries

Access to Document

Other files and links

Fingerprint

Cite this